These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1369122)

  • 41. Efficiency of antisense oligonucleotide drug discovery.
    Bennett CF
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):215-24. PubMed ID: 12162703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antisense oligonucleotides: a new therapeutic approach.
    Temsamani J; Guinot P
    Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An overview of progress in antisense therapeutics.
    Crooke ST
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049
    [No Abstract]   [Full Text] [Related]  

  • 44. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
    Crooke RM; Graham MJ; Cooke ME; Crooke ST
    J Pharmacol Exp Ther; 1995 Oct; 275(1):462-73. PubMed ID: 7562586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oligonucleotide pharmacotherapy: an antigene strategy.
    Nagel KM; Holstad SG; Isenberg KE
    Pharmacotherapy; 1993; 13(3):177-88. PubMed ID: 8321732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.
    Wagner RW; Matteucci MD; Lewis JG; Gutierrez AJ; Moulds C; Froehler BC
    Science; 1993 Jun; 260(5113):1510-3. PubMed ID: 7684856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
    Agrawal S
    Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical and clinical pharmacology of antisense oligonucleotides.
    Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
    Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antisense oligonucleotides for haematological malignancies.
    Cotter FE
    Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapeutic oligonucleotides with polyethylene glycol modifications.
    Winkler J
    Future Med Chem; 2015; 7(13):1721-31. PubMed ID: 26465713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM
    Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
    Soler M; McHutchison JG; Kwoh TJ; Dorr FA; Pawlotsky JM
    Antivir Ther; 2004 Dec; 9(6):953-68. PubMed ID: 15651754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of syncytium formation by antisense oligonucleotide phosphorothioates complementary to tax mRNA of human T-cell leukemia virus type 1 (HTLV-1).
    Maeda N; Hoshino H; Kushida S; Miyano-Kurosaki N; Yamamoto N; Yokota T; Mizuguchi M; Makino K; Uchida K; Miwa M
    Leukemia; 1997 Apr; 11 Suppl 3():42-4. PubMed ID: 9209291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
    Delihas N
    Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
    Jepsen JS; Sørensen MD; Wengel J
    Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
    Geary RS; Norris D; Yu R; Bennett CF
    Adv Drug Deliv Rev; 2015 Jun; 87():46-51. PubMed ID: 25666165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacology of Antisense Drugs.
    Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.